The pharmaceutical group's recently launched generic drug Xyrem is key to this prediction, bringing a potentially $100 million or more opportunity for Generics, weighted to the first half during the 180-day exclusivity period, RBC says. The Canadian bank forecasts 8% earnings growth for the group a year from 2023 to 2028, which it doesn't believe is adequately reflected in Hikma's current share price. RBC retains its outperform rating and 1,950 pence price target. "Even though visibility remains poor, we believe it is credible that such an outcome could be matched in 2H. This suggests possible decent upside to current full year expectations," they say.

Source: Wall Street Journal April 29, 2023 04:39 UTC